FDA grants ap­peal for Arde­lyx chron­ic kid­ney dis­ease drug af­ter Ju­ly 2021 re­jec­tion

The FDA be­stowed good tid­ings up­on Arde­lyx’s ex­per­i­men­tal chron­ic kid­ney dis­ease drug Thurs­day morn­ing.

Reg­u­la­tors told the biotech they would hear an ap­peal to its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER